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Abstract
Background: Despite blood transfusion being a lifesaving option, it may be associated with blood borne infections including 
human cytomegalovirus(HCMV). The World Health Organization recommends screening of  blood products for HCMV before 
transfusion to pregnant women, neonates and immunocompromised patients. However, this is not routinely practised in many 
resource limited countries.
Objective: This study aimed at determining seroprevalence of  specific HCMV IgM antibodies among volunteered blood do-
nors at the Lake Victoria zone blood transfusion centre
Methods: A total of  228 sera from volunteered blood donors were analyzed using HCMV IgM µ capture enzyme linked immu-
nosorbent assay as per manufacturer’s instructions. Data were analyzed by STATA version 13
Results: The median age of  the study participants was 19 interquartile range (IQR): 18-23 years. The seroprevalence of  specific 
HCMV IgM antibodies was found to be 23/228 (10.1%, 95% confidence interval (CI): 6-14. None of  the factors was found to 
be associated with HCMV IgM seropositivity among blood donors.
Conclusion: One out 10 blood donors in the Lake Victoria zone blood transfusion centre is acutely infected with HCMV. There 
is a need to consider screening of  HCMV before blood transfusion particularly in resource limited countries where HCMV is 
endemic.
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Blood transfusion is a medical intervention with an es-
sential role in patient management particularly in emer-
gency cases. Although it is lifesaving, it may be a potential 
risk for transmitting blood borne infections1. The World 
Health Organization (WHO)  recommends that blood 
for transfusion should be screened for blood-borne infec-
tions such as  Hepatitis C Virus, Hepatitis B Virus (HBV), 
Treponema pallidum, and Human Immunodeficiency Virus 
(HIV) on routine basis2. In addition, the WHO also rec-
ommends that blood to be transfused to neonates, preg-
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nant women and immunocompromised patients should 
be screened for Human cytomegalovirus (HCMV)3. 
However, in most of  resource limited countries HCMV 
is not considered in any of  these cases. HCMV infec-
tion in infants is associated with meningitis, pneumonia 
and sepsis while infection in pregnant women may lead 
to congenital infections that may cause life threatening 
congenital anomalies. Furthermore, HCMV infection in 
immunocompromised individuals is associated with se-
vere life threatening diseases such as meningitis and sep-
sis4-76, 8-11. It should be noted that, in  immunocompetent 
individuals, acute primary HCMV infection is often self  
limited followed by latency mostly in CD34+ haemopoi-
etic progenitor cell in bone marrow and CD13+, CD14+ 
peripheral blood mononuclear cells with potential of  re-
activation during immunocompromised state12.
 
Tanzania, like many other resource limited countries, 
the blood donors are not routinely screened for HCMV. 
Nonetheless, the donated blood has been also used for 
the management of  pregnancy related anemia, immuno-
compromised patients as well as neonates in need. This 
poses a potential risk for transfused individuals which 
might be associated with life threatening clinical mani-
festations13,14. Despite HCMV being reported in a signifi-
cant proportion of  blood donors in many of  the endemic 
countries15-17,  there is no routine HCMV screening with 
limited data among blood donors in Tanzania. This has 
prompted us to investigate the seroprevalence of  acute/
recent HCMV infection among blood donors to provide 
appropriate recommendations for policy makers to con-
sider it in screening particularly in case blood units are 
needed by vulnerable groups. 
Methods
Study design, study area, sample size and ethical 
considerations
A cross-sectional study using 228 achieved sera collect-
ed from blood donors aged 18 years collected  between 
March 2016 and July 2017 was conducted in the city 
of  Mwanza. The sample size was  calculated using the 
Kish Leslie formula a prevalence of  12.2% from a pre-
vious study in Burkina-Faso was fitted in the formula18. 
The minimum sample size was 169, however a total of  
228 sera were retrieved and include into the study. Sera 
were conveniently selected until desired sample size was 
reached. All sera with incomplete information were ex-
cluded from the study. Socio-demographic and other rel-
evant information were recorded from preexisting data-
base. The protocol to conduct this study was approved 
by the joint CUHAS/BMC research ethics and review 
committee (CREC) with ethical clearance number CREC 
340/2017.
Laboratory processing of  the specimens
Detection of  specific HCMV IgM antibodies was done 
using commercial IgM µ capture enzyme linked immu-
nosorbent assay (ELISA) according to manufacturer’s in-
structions (PishtazTeb, Tehran, Iran). The assay has sen-
sitivity and specificity of  >99%19-22.
Data analysis
Data was analyzed by using STATA version 13. Continous 
variables were summarized as median with interquartile 
range while categorical variables were summarized as 
proportions. Chi square test was used to test association 
between outcome and independent variables
Results
The median age of  the study participants was 19(IQR:18-
23) years. Male sex was more predominant 84.65% 
(193/228) compared to female sex. Most of  the partici-
pants, 74.12% (169/228) were students (Table 1).
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Table 1: Characteristics of 288 blood donors attended at  
Victoria zone blood transfusion center in Mwanza, Tanzania 
 
Participant characteristics Number(Frequency) Median (%) 
Age 228 19 (IQR:18-23) 
Sex:              Female 
                      Male 
35 
193 
                   15.35% 
                   84.65% 
Occupation: Workers 
                       Students 
59 
169 
                   25.88% 
                   74.12% 
CMV IgM: Negative 






The overall seroprevalence of  specific HCMV IgM an-
tibodies was found to be 23/228 (10.09%, 95% CI: 
6-14). Out of  35 females, 2(5.7%) were IgM seroposi-
tive compared to 21(10.9%) of  193 males, P=0.35. Re-
garding occupation, 13.6% of  59 workers were seropos-
itive compared to 8.9% of  169 students, P=0.304.  The 
seroprevalence in age (years) groups;16-25, 26-45 and 36-45 
were 10.1%, 12.9% and 9.1%, respectively.  On Wilcox-
on ranksum (Man Whitney) test, there was no significant 
difference in age among positive cases and negative cases 
(19, IQR: 18-25 vs. 19, IQR: 18-22, P>0.05). Among so-
cio-demographic characteristics assessed, none of  them 
was found to be associated with HCMV IgM seropositiv-
ity among blood donors in the Lake Victoria zone blood 
transfusion center.
Discussion
This is the first study to establish the seroprevalence of  
specific HCMV IgM antibodies among blood donors in 
the Lake Victoria zone blood transfusion center. In the 
current study, a significant proportion of  blood donors 
had specific IgM antibodies which often indicate acute 
or recent infections. Results from the current study are 
comparable to a previous report from Ouagadougou 
Burkina Faso which reported the prevalence of  12.2%18. 
In comparison to other previous studies, the reported se-
roprevalence in this study is lower than 85% and 28% 
reported in North-West Iran and in Nigeria16,23.  On the 
contrary, the reported seroprevalence in this study is in-
deed high compared to the previous reports in India and 
Kenya which documented the seroprevalence of  0.07% 
and 3.6%, respectively15,24.  The possible explanation for 
these variations could be geographical variations, climatic 
and socio-economic backgrounds which might influence 
the epidemiology of  the HCMV25,26. Another explanation 
could be sensitivity and specificity of  the test used in dif-
ferent studies. In the current study, IgM µ capture ELI-
SA was used with sensitivity and specificity of  100% and 
99%, respectively which might be different from other 
studies. Considering the fact that HCMV is not routine-
ly screened in most of  resource limited countries where 
the prevalence is high, this might increase the risk of  
transmission to vulnerable groups such as immunocom-
promised patients, neonates and pregnant women. This 
underscores the need to consider screening for HCMV 
in donated blood before transfusion particularly in vul-
nerable groups.
In the current study, none of  the socio-demographic 
factors assessed was found to be associated with HCMV 
IgM seropositivity. This could be explained by the fact 
that the current study used achieved sera which might 
limit accessibility of  other information from the study 
participants.  Further studies to explore more on the risk 
factors are recommended in this setting.
Conclusion and recommendations
A substantial proportion of  blood donors in the Lake 
Victoria zone blood transfusion centre is acutely infected 
with HCMV which calls for the need to consider screen-
ing for HCMV before the donated blood is transfused to 
recipients especially vulnerable groups. Further studies to 
explore more on the risk factors are highly recommended 
in this setting.
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